Featured Articles

1. Process Optimization And Scalability Evaluation Of Pellicon® Capsules For SPTFF Of mAb-Based Biomolecules 6/17/2022

   This document describes the principles of SPTFF and how to determine operating conditions to achieve the target concentration factor with single-use Pellicon® Capsules.

2. Ultrafiltration/Diafiltration In The Antibody Drug Conjugate Manufacturing Process 6/17/2022

   We review a single-use TFF device that increases operator safety, and also saves time for improved batch turnaround and flexibility in the ADC manufacturing plant.

3. Enhancing Ease Of Use Batch Turnaround And Process Flexibility With Single-Use TFF 6/17/2022

   Use of single-use Pellicon® Capsules is an effective strategy for improving operational flexibility, product safety, and turnaround of a TFF step.

4. Frontiers In Digital Bioprocessing: Modular Plant Automation And Cloud 5/26/2022

   As the biopharmaceutical industry is embracing digital transformation and thus evolves in its digital maturity, future-ready concepts will play a leading role in the shift toward bioprocessing 4.0.

5. Orchestration For Remote Access And Monitoring Of Bioprocess Unit Operations 5/26/2022

   Digital transformation projects require a scalable connectivity solution for the manufacturing floor that is easily and rapidly deployed. Explore future-ready, flexible, deployable, and reconfigurable elements that enable connectivity among equipment.

6. One Size Does Not Fit All: Utilizing Multiple Technology Providers In Gene Therapy Manufacturing 5/19/2022

   With a diverse landscape of potential partners, it is important to know what qualities to look for in a technology provider and how to traverse the challenges inherent in managing multiple relationships.

7. Bioprocessing And Scaleup Of HEK293 Cells For AAV Production 5/9/2022

   MilliporeSigma has developed the VirusExpress®️ AAV Production Platform as a scalable upstream AAV production solution for viral gene therapies.

8. Viral Clearance Considerations For Adeno-Associated Virus (AAV) Viral Vectors 4/11/2022

   There is no one-size-fits-all model for AAV gene therapy products when it comes to viral clearance studies. Here we address some of the questions with respect to viral clearance studies for AAV vectors.

9. Lay The Proper Foundation For Upstream Success 4/7/2022

   When selecting a partner for development of upstream processes you need speed, quality and regulatory compliance – all appropriately balanced.

10. A Platform Standard For Viral Vector Manufacturing And Commercialization 4/6/2022

    Learn more about platform technologies that are being developed and implemented to support large-scale production of viral vectors.